Document:

Employment Agreement by BioMarin Pharmaceutical Inc. and G. Eric Davis

 Exhibit 10.6 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT made as of April 9, 2007 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and G. Eric Davis (“Employee”). 
 WHEREAS, Company and Employee wish to amend and restate the current terms of Employee’s terms of employment by the Company. 
 NOW THEREFORE, for good and valuable consideration (the receipt and adequacy of which are hereby acknowledged and agreed) the parties hereby covenant and agree as follows: 
 1. Title; Duties. The Company hereby employs the Employee as Vice President, General Counsel to perform such duties consistent with his title and
position as may be determined and assigned to him by the Company’s Chief Executive Officer (“CEO”). The Employee shall be based in Novato, California, provided that Employee acknowledges that his job duties may require
significant travel. 
 2. Time and Effort. The Employee agrees to devote substantially all of his professional employment time and
effort to the performance of his duties as Vice President, General Counsel for the Company and to perform such other duties consistent with his title and position as are reasonably assigned him from time to time by the CEO. 
 3. Term. The Company agrees to employ the Employee in accordance with the terms of this Agreement, which terms shall be effective commencing on
the Effective Date and continuing thereafter until terminated pursuant to Section 6 or 7 hereof (the “Term” of this Agreement). A review of the Employee’s total compensation will be made by the Board of
Directors of the Company (“Board”) at least annually in or about December of each year based on the overall performance of the Company and the Company’s assessment of the Employee’s contributions to the Company’s
performance, although the Board shall not be under any obligation to make adjustments other than pursuant to its discretion. 
 4.
Compensation; Benefits. 
 (a) Base Salary. For all the services to be rendered by the Employee in any capacity hereunder,
including services as an executive officer, the Company agrees to pay the Employee a base salary (“Base Salary”) of not less than two hundred seventy-six thousand nine hundred dollars ($276,900) per annum. Base Salary shall be
payable in approximately equal installments in accordance with the Company’s customary payroll practices. The foregoing annual compensation amount may be, from time to time, adjusted above the Base Salary specified above by action of the Board
or appropriate Committee of the Board. In the event the Base Salary is adjusted upward by the Board, such adjusted amount will be deemed to be the new Base Salary. 
 (b) Bonus. The Employee shall be entitled to participate in the Company’s generally applicable employee bonus program, with such targets and metrics as may be approved by the Board from time to time.

 (c) Benefits Plans. The Employee also shall participate fully in all insurance, pension, retirement, deferred compensation, stock
and stock option, stock purchase or similar compensation and benefit plans and programs pursuant to the terms of such plans or programs. 
 (d) Vacation. The Employee shall be entitled to annual paid vacation time of four (4) weeks, accruing ratably over the course of each year of employment, to be taken at such time or times as the Employee may select, consistent
with his obligations hereunder. Vacation days not taken during an applicable fiscal year may be carried over to the extent permitted under the Company’s vacation policy to the following fiscal year pursuant such policy. 
 (e) Expenses. The Company shall reimburse the Employee for all reasonable and customary travel, business and entertainment expenses incurred in
connection with the Employee’s performance of his services hereunder in accordance with the policies and procedures established by the Company. 
 (f) Withholding. The amounts payable pursuant to this Agreement shall be subject to withholding for appropriate taxes, assessments or withholdings as required by applicable law. 

 5. Other Plans. The Company and the Employee hereby agree that nothing contained herein is
intended to or shall be deemed to affect any of the Employee’s rights as a participant under any retirement, stock option, stock purchase, pension, insurance, profit-sharing or similar plans of the Company now or hereafter declared to be in
effect. The Company recognizes that the Employee is induced to execute this Agreement and to accept compensation at the rate set forth herein in part because he expects to be a participant under such plans as are, from time to time, in effect for
the Company’s executives and/or employees in general. 
 6. Termination for Cause; Resignation Without Good Reason. 

(a) Termination for Cause. This Agreement may be terminated for Cause (as defined below) by the Company before the expiration of the Term
provided for herein if, during the Term of this Agreement, the Employee (i) materially violates the provisions of the Non-Competition Agreement or the Confidentiality Agreements between the Company and Employee, (ii) is convicted of, or
pleads nolo contendere to, any crime involving misuse or misappropriation of money or other property of the Company or any felony; (iii) exhibits repeated willful or wanton failure or refusal to perform his duties in furtherance of the
Company’s business interest or in accordance with this Agreement, which failure or refusal is not remedied by the Employee within thirty (30) days after notice from the Company; (iv) commits an intentional tort against the Company,
which materially adversely affects the business of the Company; (v) commits any flagrant act of dishonesty or disloyalty or any act involving gross moral turpitude, which materially adversely affects the business of the Company; or
(vi) exhibits immoderate use of alcohol or drugs which, in the opinion of an independent physician selected by the Company, impairs the Employee’s ability to perform his duties hereunder (all of the foregoing clauses (i) through
(vi) constituting reasons for termination for “Cause”), provided that unsatisfactory business performance of the Company, or mere inefficiency, or good faith errors in judgment or discretion by the Employee shall not constitute
grounds for termination for Cause hereunder. In the event of a termination for Cause, the Company may by written notice immediately terminate his employment and, in that event, the Company shall be obligated only to pay the Employee the compensation
due him up to the date of termination, all accrued, vested or earned benefits under any applicable benefit plan and any other compensation to which the Employee is entitled under Section 4 up to and ending on the date of the
Employee’s termination. 
 (b) Resignation Without Good Reason. The benefits and compensation set forth in
Section 6(a) are the only compensation and benefits that the Employee will receive in the event that Employee resigns without Good Reason (as defined below). If the Employee resigns without Good Reason prior to a Change in Control (as
defined in the Company’s Change of Control Policy), the Employee agrees to give the Company at least four (4) weeks’ prior notice and in exchange the Company agrees to pay the Employee for all compensation Employee would be entitled
to pursuant to Section 4 for such four (4)-week period as if Employee had not resigned without Good Reason. Any resignation of the Employee hereunder, whether for Good Reason or otherwise, shall be deemed to include a resignation from
all positions and in all capacities with the Company and its subsidiaries, including, without limitation, membership on the boards of directors (and committees thereof) of subsidiaries of the Company, and the Employee shall execute such
documentation as requested by the Company with respect thereto. 
 7. Termination Without Cause; Resignation For Good Reason; Disability;
Death. 
 (a) Termination Without Cause; Resignation For Good Reason. The Company may terminate the Employee’s employment at
any time for any reason or no reason, upon written notice to the Employee. If (i) the Company terminates the Employee’s employment without Cause at any time prior to the end of the Term of the Agreement, or (ii) the Employee provides
the Company with written notice (a “Notice of Termination”) of his resignation for Good Reason (as defined below) at least four (4) weeks prior to the date of termination, or (iii) there is a substantial change in the
financial condition of the Company as evidenced only by the Company filing a petition for reorganization under any bankruptcy, insolvency, reorganization or similar law or making an assignment for the benefit of creditors, then the Employee shall
receive the Termination Compensation (as defined below). 
 (b) Resignation for Good Reason. A resignation for any one or more of the
following events, without the written consent of Employee or his approval of such event in his capacity as Vice President, General Counsel, shall be referred to herein as “Good Reason”: 
 (i) a change in the Employee’s title or a substantial reduction in the Employee’s duties, status, in either case by reference to the position
held by the Employee on the Effective Date; 
 (ii) a relocation of the Employee’s assigned office more than fifty (50) miles from
its then-current location; 
 (iii) any decrease in the Employee’s Base Salary or a material decrease in his Company benefits in the
aggregate, other than as part of a reduction (not exceeding twenty-five percent) that equitably applies to all of the Company’s executive officers; 

 (iv) a failure by any successor-in-interest to assume the Company’s obligations under this
Agreement; or 
 (v) a material breach of this Agreement by the Company; 
 provided, however, that an event that is or would constitute grounds for a resignation for Good Reason shall not constitute such grounds for a resignation for Good Reason if: (1) the Employee does
not send a Notice of Termination to the Company within forty-five (45) days after the event occurs; or (2) the Company reverses the action or cures the default that constitutes Good Reason within twenty (20) days after the delivery of
the Notice of Termination. 
 (c) Termination Compensation. For purposes of this Agreement, the term “Termination
Compensation” shall mean: (i) one hundred percent (100%) of Employee’s then current annual base salary plus (ii) one hundred percent (100%) of the greater of the actual cash bonus paid to employee attributable to
the prior year’s service or Employee’s target cash bonus for the current year, all of which shall be payable in a lump sum within 2 weeks after separation of employment, conditioned on Employee executing the Company’s standard form
severance and release agreement, and shall be subject to customary withholding and other applicable payroll processes. 
 (d)
Employee’s Disability. The Company shall be entitled, by providing written notice to the Employee, to terminate the Employee’s employment under this Agreement if the Employee shall become permanently disabled such that he is unable
to carry out his duties hereunder for four (4) consecutive calendar months or for a period aggregating one hundred twenty (120) days in any period of twelve (12) consecutive calendar months. If the Employee is eligible to receive
benefits under the Company’s Long-Term Disability Plan, then the Company will pay the Employee additional compensation so that the total received by the Employee (after taking into consideration the amounts payable to the Employee under the
Long-Term Disability Plan) equals the Termination Compensation. If the Employee is not eligible to receive benefits under such plan, then he will upon termination of his employment for permanent disability be entitled to receive the full Termination
Compensation. Any delay or forbearance by the Company in exercising any such right to terminate this Agreement shall not constitute a waiver thereof. 
 (e) Employee’s Death. The Employee’s employment will immediately terminate upon the death of the Employee. The Employee’s surviving designated beneficiary, or, if none, the Employee’s
estate, shall be entitled to receive the compensation due the Employee up to the date of the Employee’s death, all accrued, vested or earned benefits under any applicable benefit plan and any other compensation to which the Employee is entitled
under this Agreement up to and ending on the date of the Employee’s death. 
 8. Choice of Law; Venue. This Agreement shall be
construed and performed in accordance to the laws (but not the conflicts of laws) of the State of California. Venue of any proceeding shall be exclusively in the County of Marin in the foregoing state, and both parties consent and agree to such
exclusive venue. 
 9. Arbitration.  
 (a) The Employee and the Company understand that litigation is a costly and time-consuming process and agree that they will exclusively resolve any disputes between them by binding arbitration. The Employee and the
Company understand that this agreement to arbitrate covers all disputes that the Company may have against the Employee, or that the Employee might have against the Company or its related entities or employees, including those that relate to the
Employee’s employment or termination of employment (for example claims of unlawful discrimination or harassment). 
 (b) The arbitration
will be conducted by an impartial arbitrator experienced in employment law (selected from either the JAMS or the American Arbitration Association (at the Company’s election) panel of arbitrators) in accordance with the applicable entity’s
then current employment arbitration rules (except as otherwise provided in this agreement or unless the parties agree to use the then-current commercial arbitration rules). The Employee and the Company waive the right to institute a court action,
except for requests for injunctive relief pending arbitration, and understand that they are giving up their right to a jury trial. The parties shall be entitled to reasonable discovery. The arbitrator’s award and opinion shall be in writing and
in the form typically rendered in labor and employment arbitrations. 
 (c) The Company will pay any filing fee and the fees and costs of the
arbitrator, unless the Employee initiates the claim, in which case the Employee only will be required to contribute an amount equal to the filing fee for a claim initiated in a court of general jurisdiction in the State of California. The Employee
and the Company each shall be responsible for their own attorneys’ fees and costs; provided, however, the arbitrator may award attorneys’ fees to the prevailing party, if permitted by applicable law. This arbitration
agreement does not prohibit either the Employee or the Company from filing a claim with an administrative agency (e.g., the EEOC), nor does it apply to claims for workers’ compensation or unemployment benefits, or claims for benefits
under an employee welfare or pension plan that specifies a different dispute resolution procedure. The arbitration shall take place in Marin County, California unless the Employee and the Company agree otherwise. 

 10. Notices. All notices provided for or permitted to be given pursuant to this Agreement must be
in writing. All notices shall be given to the other party by personal delivery, overnight courier (with receipt signature), or facsimile transmission (with “answerback” confirmation of transmission), to the Company or the Employee at the
Company’s principal executive offices if to the Company or to the residential address of the Employee as contained in Employee’s personnel file if to Employee. Each such notice shall be deemed effective upon the date of actual receipt in
the case of personal delivery, receipt signature in the case of overnight courier, or confirmation of transmission in the case of facsimile. 
 11. Entire Agreement; Amendment. This Agreement contains the sole and entire agreement of the parties and supersedes all prior agreements and understandings between the Employee and the Company and cannot be modified or changed by
any oral or verbal promise or statement by whomsoever made; nor shall any written modification of it be binding upon the Company until such written modification shall have been approved in writing by the CEO or the Board. 
 12. Waiver; Consent. In the event any term or condition contained in this Agreement should be breached by any party and thereafter waived or
consented to by the other party, which waiver or consent must be effectuated by a written instrument signed by the party against whom any waiver or consent is sought (and, in the case of the Company, approved by the CEO or the Board), such waiver or
consent shall be limited to the particular breach so waived or consented to and shall not be deemed to waive or consent to any other breach occurring prior or subsequent to the breach so waived or consented to. 
 13. Severability. If any provisions of this Agreement or the application thereof to any person or circumstances shall be invalid or unenforceable
to any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the extent permitted by law. 
 14. Survival. The provisions hereof which are to be performed or observed after the termination of this Agreement, and the representations,
covenants and agreements of the parties contained herein with respect thereto shall survive the termination of this Agreement and be effective according to their terms. 
 15. Successors. All of the terms and provisions of this Agreement shall be binding upon and shall inure to the benefit of and be enforceable by and against the parties to this Agreement and the respective
heirs, executors, and successors in interest; provided, however, that the duties of the Employee hereunder are personal in nature and may not be delegated without a written consent of the Company. 
 16. Assignment. This Agreement and the rights and benefits contained herein may not be assigned by either party hereto, except by the Company in
connection with a merger, consolidation, share exchange, business combination or other reorganization of the Company or a sale of all or substantially all of the Company’s business or assets. 
 17. Certain Representations, Covenants and Acknowledgements. 
 (a) The Employee represents that he is not subject to any employment, confidentiality, or other agreement or restriction that would prevent him from fully satisfying his duties under this Agreement or that would be
violated if he did so. 
 (b) Without the Company’s prior written approval, the Employee agrees not to: (i) disclose proprietary
information belonging to a former employer or other entity without its written permission; (ii) contact any former employer’s customers or employees to solicit their business or employment on behalf of the Company; or (iii) distribute
announcements about or otherwise publicize his employment with the Company. 
 (c) The Employee acknowledges that he is free to seek advice
from independent counsel with respect to this Agreement and the Employee has obtained such advice. The Employee is not relying on any representation or advice from the Company or any of its officers, directors, attorneys or other representatives
regarding this Agreement, its content or effect. 
 18. Construction. The masculine pronoun, wherever used herein, shall be construed
to include the feminine and the neuter, where appropriate. The singular form, wherever used herein, shall be construed to include the plural, where appropriate. 
 19. Drafting. The parties represent and acknowledge that they both have participated in the preparation and drafting of this Agreement and have each given their approval to all of the language contained in this
Agreement, and it is expressly agreed and acknowledged that if either party later claims that there is an ambiguity in the language of this Agreement, there shall be no presumption that such ambiguity be construed for or against either party hereto.

 20. Counterparts. This Agreement may be executed and delivered (including by facsimile
transmission) in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement as of the date first written above. 
  

					
	 BIOMARIN PHARMACEUTICAL INC.
	 	
			
	By:	 	 /s/ JEAN-JACQUES BIENAIMÉ
	 	
	Name:	 	Jean-Jacques Bienaimé	 	
	Its:	 	Chief Executive Officer	 	
		
	 EMPLOYEE
	 	
			
	By:	 	 /s/ G. ERIC DAVIS
	 	
		 	G. Eric DavisLicense Agreement

 Exhibit 10.7 
 CONFIDENTIAL TREATMENT REQUESTED 
 Redacted portions are indicated by [****] 
 LICENSE AGREEMENT 
 This LICENSE AGREEMENT
(this “Agreement”) is dated as of February 7, 2007 (the “Effective Date”) by and between Women’s and Children’s Hospital, a facility of Children, Youth and Women’s Health Service incorporated
under the South Australian Health Commission Act 1976, having its principal place of business at 72 King William Road, North Adelaide, South Australia, Australia (hereinafter referred to as “WCH”), and BioMarin Pharmaceutical Inc.,
a Delaware corporation, having its principal place of business at 105 Digital Drive, Novato, California 94949 (hereinafter referred to as “BioMarin”). 
 INTRODUCTION 
 WHEREAS, WCH owns the WCH Licensed Product and Licensed Technology; and

 WHEREAS, BioMarin and WCH entered into that certain License Agreement dated August 14, 1998 (the “License
Agreement”), wherein WCH agreed to grant to BioMarin an exclusive worldwide license to the WCH Licensed Technology for the commercialization of the Licensed Product in accordance with the terms and conditions set forth in the License
Agreement; and 
 WHEREAS, BioMarin and WCH desire to enter into this Agreement, which shall supercede the License Agreement, to
define the terms and conditions under which WCH shall grant BioMarin an exclusive, worldwide, perpetual, royalty -bearing license to the Licensed Product and Licensed Technology. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, WCH and BioMarin agree as follows: 
 Article I. DEFINITIONS 
 As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 
 1.1 “Affiliate” means any person, corporation, company, partnership, joint venture, firm or other entity which controls, is controlled by or is under
common control with a Party. For purposes of this Section 1.1, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) (or such lesser percentage that
is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the stock or shares entitled to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at
least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 
 1.2
“BioMarin Improvement” means variations, updates, modifications, and enhancements developed, conceived or reduced to practice by BioMarin as related to the use of rhASB, including, without limitation, any and all developments,
enhancements, modifications, inventions or discoveries, to methods of treatment, purification and production for rhASB to the extent such methods of treatment, purification or production are not related to the host cell line which expresses rhASB.
For the avoidance of doubt, any improvements or inventions related to or made in the course of developing the Licensed Products and during the term of the License Agreement are either BioMarin Improvements or Licensed Technology, as applicable.

 1.3 “BioMarin Improvement Patent Rights” means any United States or foreign patent or patent application which discloses or claims a
BioMarin Improvement. 
 1.4 “BioMarin Indemnitee(s)” shall have the meaning set forth in Section 9.4(b). 
 1.5 “Commercially Reasonable Efforts” means, with respect to the research, development, manufacture, or commercialization of Licensed Product, efforts
and resources commonly used in the research-based pharmaceutical industry for a compound or product of similar commercial potential at a similar stage in its lifecycle, taking into consideration its safety and efficacy, its cost of development, the
competitiveness of alternative products, its proprietary position, the likelihood, expense and time required to obtain regulatory and reimbursement approval, its profitability, and other relevant factors. Commercially Reasonable Efforts shall be
determined on a market-by-market basis. 

 1.6 “Confidential Information” means trade secrets, know how and other confidential information
(including, without limitation, technical and business information, patent information, structures, models, techniques, formula, processes, compositions, compounds, apparatus, specifications, samples, inventions and ideas) of either Party which
relates to the subject matter of this Agreement, including without limitation the Licensed Product, Licensed Technology and any BioMarin Improvements, whether or not marked as proprietary or confidential, disclosed by the disclosing Party or
obtained through observation or examination of the disclosing Party’s information or developments, or which, although not related to such subject matter, is nevertheless disclosed as a result of the Parties’ discussions but only to the
extent that such information is maintained as confidential by the disclosing Party. Confidential Information may be disclosed orally, visually or in tangible form (whether by document, electronic media, or other form). 
 1.7 “Indemnify” shall have the meaning set forth in Section 9.4(a). 
 1.8 “Indemnifying Party” shall have the meaning set forth in Section 9.4(c). 
 1.9
“Indemnitee(s)” shall have the meaning set forth in Section 9.4(c). 
 1.10 “Inventions” shall have the meaning
set forth in Section 5.1. 
 1.11 “Licensed Product” means recombinant human enzyme N-acetylgalactosamine-4- sulfatase (rhASB)
and its precursor (collectively and separately referred to herein as rhASB) and compositions comprising same that are developed from or utilizes any part of the Licensed Technology. 
 1.12 “Licensed Technology” means all developments, enhancements, know-how, modifications, inventions, improvements, and discoveries in the control of WCH as of August 14, 1998 related to the
Licensed Product development before August 14, 1998 and methods of production or purification of Licensed Product developed after August 14, 1998, but only to the extent applicable to the host cell line which expresses rhASB or a daughter
cell line thereof, including the patent and patent applications listed in Exhibit A, attached hereto. 
 1.13 “Losses” shall have the
meaning set forth in Section 9.4(a). 
 1.14 “Net Sales” means [****] 
 1.15 “Party” means WCH or BioMarin; “Parties” means WCH and BioMarin. 
 1.16 “rhASB” means recombinant human enzyme N-acetylgalatosamine 4-sulfatase. 
 1.17
“Term” shall have the meaning set forth in Section 8.1. 
 1.18 “Territory” means the entire world. 

1.19 “Third Party” means any entity other than WCH, BioMarin, and their respective Affiliates. 
 1.20 “WCH Indemnitee(s)” shall have the meaning set forth in Section 9.4(a). 
 Article II. LICENSE 
 2.1 Grant to BioMarin. Subject to the terms and conditions of this
Agreement, WCH hereby grants to BioMarin and its Affiliates an exclusive, perpetual, nontransferable, royalty -bearing license, with the right to grant sublicenses, under the Licensed Technology to make, have made, develop, use, distribute, lease,
promote, offer to sell, sell, have sold, import or export Licensed Products in the Territory. 
 2.2 Notice of Sublicense. BioMarin shall provide WCH
with prompt written notice of any sublicense of the rights granted to BioMarin herein to the extent that such sublicense could result in the sublicense generating Net Sales, including an identification of the sublicensee and a description of the
rights sublicensed. Information regarding any such sublicense shall be Confidential Information of BioMarin. 
 2.3 Diligence. BioMarin shall exercise
Commercially Reasonable Efforts to develop and commercialize the Licensed Product. 
 2.4 No Further Rights. Except as explicitly provided in this
Article II and III, no further license or right, express or implied, is granted by either Party hereunder. 

 Article III. DEVELOPMENT 
 3.1 BioMarin will be responsible for the development and production of the Licensed Product and for world wide supply and commercialization related to the Licensed Product. WCH hereby grants and BioMarin accepts the
right to sublicense the Licensed Product to ensure BioMarin can enter into partnerships or business collaborations, which involves the manufacture, marketing, sales, and distribution of the Licensed Products. 
 Article IV. PAYMENTS 
 4.1 Fees to WCH. In
consideration of the license set forth in Article II above, BioMarin shall pay to WCH nonrefundable earned royalties as set forth below on Net Sales of Licensed Product: 
  

	 	(a)	[****] 

  

	 	(b)	[****] 

 4.2 Royalty Term. BioMarin obligation to pay earned
royalties to WCH under this Agreement shall commence on the Effective Date and [****] 
 Article V. INTELLECTUAL PROPERTY 
 5.1 Ownership of Inventions. WCH shall have and retain sole and exclusive title to all inventions, discoveries and know-how (“Inventions”) which are
made by either party, its employees, agents or other parties acting under authority from either party specifically relating to the Licensed Product. 
 5.2
BioMarin Improvements. All right, title and interest to BioMarin Improvements shall remain vested in BioMarin. WCH shall take such actions as BioMarin may reasonably request to vest title to BioMarin Improvements with BioMarin. 
 5.3 Prosecution of Patent Rights. BioMarin shall have the right, but not the obligation, to (in its sole discretion) file, obtain, prosecute, extend and maintain,
at its sole cost and expense, patents and patent applications, including all divisional, continuation and continuation-in-part applications for Inventions, BioMarin Improvement Patent Rights and the Licensed Technology throughout the world. BioMarin
shall forward to WCH copies of any material correspondence received from the United States or foreign patent offices with respect to the Licensed Technology for those patents and patent applications which, but for the license granted under this
Agreement, the manufacture, use or sale of Licensed Product, would infringe. WCH shall have the right to comment on and to discuss prosecution and maintenance activities with BioMarin, and, if such comments and advice are timely offered by WCH,
BioMarin shall consider the same in good faith, but shall not be obligated to implement any comments and advice so offered by WCH. In addition, WCH agrees that it will not perform any act that is deleterious to BioMarin’s efforts to prosecute
the patents for Inventions, BioMarin Improvement Patent Rights or Licensed Technology or defend or enforce a claim within patents for the WCH Licensed Technology; nor, initiate any procedure that could result in the invalidation or unenforceability
of any claim related to patents for Licensed Technology. 
 5.4 Enforcement of Patent Rights. 
 (a) Notice. Each Party shall promptly report in writing to the other Party during the Term of this Agreement any suspected infringement of the
patent rights for Licensed Technology or BioMarin Improvement Patent Rights of which it becomes aware, and shall provide the other Party with all available evidence supporting such suspected infringement or unauthorized use. 
 (b) Enforcement of Patent Rights. BioMarin shall have the right, but not the obligation, to initiate and control patent infringement proceedings
or to otherwise enforce the rights in BioMarin Improvement Patent Rights or Licensed Technology against any Third Party who at any time is suspected of infringing BioMarin Improvement Patent Rights or Licensed Technology. Further and in such case,
BioMarin shall keep WCH informed, and shall from time to time consult with WCH regarding the status of any such suit and, upon request, shall provide WCH, at BioMarin’s expense, with copies of all documents filed in, and all material written
communications between the parties relating to, such suit. If necessary, upon request by BioMarin, WCH shall join as a party to the suit. Also, upon reasonable request by BioMarin, WCH shall reasonably cooperate with BioMarin to execute all
necessary and proper documents and take all other appropriate action required to institute and prosecute such action. BioMarin will promptly reimburse 

 
WCH for any reasonable costs incurred by WCH to join as a party or to cooperate with BioMarin in the institution and/or prosecution of such action; provided,
however, that such costs are incurred at the request of BioMarin and appropriate detailed supporting documentation is provided to BioMarin by WCH. 
 (c) Selection of Counsel and Payment of Expenses. BioMarin shall have the sole and exclusive right to select BioMarin counsel for any suit referred to in Section 5.2(b) of this Agreement and shall pay all expenses of the
suit, including attorneys’ fees and court costs. Any damages, royalties, settlement fees or other consideration received by BioMarin with respect to such suit shall be retained solely by BioMarin. 
 5.5 Alleged Infringement of Third Party Patent Rights.  
 (a) In the event that a Third Party institutes a patent infringement suit against BioMarin, its Affiliates, or sublicensees, as a result of BioMarin’s, its Affiliates’, or sublicensee’s exercise of its
rights under this Agreement, BioMarin shall have the sole right to defend such suit. BioMarin shall pay all expenses of the suit, including attorneys’ fees and court costs. Any damages, royalties, settlement fees or other consideration received
by BioMarin with respect to the suit shall be retained solely by BioMarin. Upon the request of BioMarin, and at BioMarin’s expense, WCH shall use reasonable efforts to assist and cooperate with BioMarin in connection with the defense of such
suit. 
 (b) In the event that a Third Party institutes a patent infringement suit against WCH, its Affiliates, or sublicensees, as a result
of WCH’s, its Affiliates’, or sublicensee’s exercise of its rights under this Agreement, WCH shall have the sole right to defend such suit. WCH shall pay all expenses of the suit, including attorneys’ fees and court costs. Any
damages, royalties, settlement fees or other consideration received by WCH with respect to the suit shall be retained solely by WCH. Upon the request of WCH, and at WCH’s expense, BioMarin shall use reasonable efforts to assist and cooperate
with WCH in connection with the defense of such suit. 
 Article VI. ROYALTY REPORTS AND PAYMENTS 
 6.1 Royalty Reports. BioMarin shall deliver to WCH within thirty (30) days after the last day of each calendar quarter in which Licensed Product is sold a
report setting forth in reasonable detail the calculation of the earned royalties payable to WCH for such calendar quarter identifying, on a country-by-country basis, the gross sales and Net Sales of Licensed Product sold by BioMarin and its
Affiliates and sublicensees, the earned royalties payable in each country’s currency, and the calculation of royalties due to WCH. For purposes of determining when a sale of any Licensed Product occurs under this Agreement, the sale shall be
deemed to occur on the date of the invoice to the purchaser of the Licensed Product. If no sales of the Licensed Product have been made during any reporting period, a statement to this effect is required. 
 6.2 Royalty Payments. All royalties due to WCH under this Agreement [****] 
 6.3 Taxes. All royalty amounts required to be paid to WCH pursuant to this Agreement shall [****] 
 6.4 Sublicense Revenue.
Regardless of whether or not BioMarin or its Affiliates sublicenses its rights under this Agreement, BioMarin or its Affiliates is/are responsible for payment of the royalties due hereunder. 
 6.5 Audit Rights. BioMarin shall permit WCH to examine BioMarin’s books and records periodically during regular business hours upon reasonable notice for the
purpose only and to the extent necessary to verify Net Sales pursuant to this Agreement. Any such examination will be made at the expense of WCH by an independent registered or company auditor who is reasonably acceptable to BioMarin and who shall
provide a report to WCH. In the event that the auditor determines that [****] 

 Article VII. CONFIDENTIAL INFORMATION 
 7.1 Treatment of Confidential Information. Each Party shall maintain in confidence the Confidential Information of the other Party and shall not disclose, divulge
or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement; provided, however, that, either Party may disclose the
Confidential Information of the other Party if such Confidential Information is required to be disclosed by the receiving Party with respect to Licensed Products: (a) to defend or prosecute litigation; (b) to file, prosecute, defend or
maintain patent(s) or patent application(s); or (c) to file for regulatory approval with a regulatory agency for Licensed Products (provided, however, that, where available, the receiving Party takes reasonable and lawful actions to avoid
and/or minimize the degree of such disclosure). Each Party agrees to exercise reasonable precautions to prevent and restrain the unauthorized disclosure of such Confidential Information by any person to whom it is permitted to disclose, and
discloses, such Confidential Information. Further, subject to receiving Party providing disclosing Party with reasonable advance notice and opportunity to challenge, limit or seek protective order for such 8.3 disclosure, receiving Party may make
such limited disclosure as is required by process of law. Receiving Party shall provide the disclosing Party with reasonable assistance in any challenge undertaken by the disclosing Party. 
 7.2 Release from Restrictions. The provisions of Section 7.1 of this Agreement shall not apply to any Confidential Information disclosed hereunder
which: 
 (a) was known to the receiving Party or any of its Affiliates prior to its date of disclosure to the receiving Party hereunder, as
demonstrated by competent evidence of the receiving Party; 
 (b) either before or after the date of the disclosure to the receiving Party
hereunder is lawfully disclosed to the receiving Party or any of its Affiliates by a Third Party who, to the receiving Party’s knowledge, had a legal right to do so at the time of such disclosure; 
 (c) either before or after the date of the disclosure to the receiving Party hereunder becomes published or generally known to the public through no
fault or omission on the part of the receiving Party or its Affiliates; or 
 (d) is independently developed by the receiving Party or any of
its Affiliates, as demonstrated by competent evidence of the receiving Party, without reference to or use of the Confidential Information of the disclosing Party. 
 7.3 Term. All obligations imposed under this Article VII shall continue in force for the term of this Agreement and for a period of five (5) years after the expiration or earlier termination of this Agreement. 

ARTICLE VIII. TERMINATION 
 8.1 Term. This
Agreement shall commence on the Effective Date and shall continue until [****] (the “Term”) unless earlier terminated in accordance with Section 8.2 or 8.3 of this Agreement. 
 8.2 Termination by BioMarin. BioMarin shall have the right to terminate its rights and obligations under this Agreement [****] 
 8.3 Termination for Breach. Each Party shall be entitled to terminate this Agreement by thirty (30) days’ written notice to the other Party in the event
that the other Party shall be in material breach of this Agreement. This Agreement shall terminate on the date corresponding to the expiration of such thirty (30) day period, unless the Party in default has cured such breach on or before such
date or is diligently undertaking substantive and progressive efforts to cure such breach on or before such date and such breach is in fact cured as soon as reasonably possible, but no later than a further thirty (30) days after the expiration
of the thirty (30) day notice period. For any breach other than a material breach of this Agreement, the non-breaching Party shall only be entitled to seek other legal remedies but shall not be entitled to seek to terminate or terminate this
Agreement. 
 8.4 Consequences of Termination. Upon any termination of this Agreement, neither Party shall be relieved of any liability or
obligations, including but not limited to obligations to pay royalties, as set forth in Article IV herein which at the time of termination has or have already accrued to the other Party. 
 8.5 Survival of Obligations. Upon the expiration or termination of this Agreement for any reason, the following sections and articles shall survive: Sections
9.4, 9.5, 9.6, 9.7, 9.9, 9.11 and Articles I, V, VII and VIII. Articles II and III shall survive any expiration or termination of the Term of this Agreement so long as the
Agreement has not been terminated by WCH pursuant to Section 8.3 prior to the expiration of the Term and that BioMarin has satisfied all its obligations prior to such expiration or termination. Termination of this Agreement pursuant to
this Article VIII is not exclusive of any other remedies a Party may have in law or in equity, including rights and remedies under the United States Bankruptcy Code. 

 ARTICLE IX. MISCELLANEOUS 
 9.1 Representations and Warranties by WCH. 
 (a) WCH hereby represents and warrants to BioMarin, as of
the Effective Date, that: (i) it has full power and authority to enter into this Agreement and grant the licenses set forth in this Agreement; and (ii) the execution and delivery of this Agreement and the performance of its obligations
hereunder do not conflict with, violate or breach or constitute a default or require consent under, any contractual obligation or court or administrative order by which WCH is bound. 
 (b) As of the Effective Date, WCH owns all right, title and interest in and to the Licensed Technology, free and clear of all liens and encumbrances;

 (c) As of the Effective Date, WCH has not granted, and shall not during the term of this Agreement grant, any license or right to any
Third Party or Affiliate with respect to the Licensed Technology or otherwise undertake any action which would conflict in any respect with the rights granted to BioMarin set forth in this Agreement; 
 (d) As of the Effective Date, no Third Party has made any claim or allegation to WCH that such Third Party has any right or interest in or to the
Licensed Technology. 
 9.2 Representations and Warranties by BioMarin. 
 (a) BioMarin hereby represents and warrants to WCH, as of the Effective Date, that: (i) it has full power and authority to enter into this Agreement; and (ii) the execution and delivery of this Agreement and
the performance of its obligations hereunder do not conflict with, violate or breach or constitute a default or require consent under, any contractual obligation or court or administrative order by which BioMarin is bound. 
 (b) BioMarin shall have and maintain such type and amounts of liability insurance covering the manufacture, supply, use and sale of the Licensed Product
as is normal and customary in the pharmaceutical industry generally for companies similarly situated, and shall, upon request, provide WCH with a copy of its current policies of insurance in that regard. 
 (c) All necessary consents, approvals and authorizations of all regulatory and governmental authorities required to be obtained by BioMarin in connection
with the commercialization of Licensed Product have been or shall be obtained in a timely manner. 
 9.3 EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 9.1
AND 9.2 AND TO THE EXTENT PERMITTED BY LAW BUT OTHERWISE WITHOUT LIMITATION, WCH AND BIOMARIN MAKE NO REPRESENTATION AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, INCLUDING,
WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 9.4 Indemnification. 
 (a) BioMarin agrees to indemnify and hold harmless (collectively “Indemnify”) and defend WCH, its agents, Affiliates, directors, officers
and employees (the “WCH Indemnitee(s)”), at BioMarin’s sole expense, from and against any and all losses, costs, damages, fees or expenses (collectively, “Losses”) arising out or in connection with (i) the
material breach of any representation or warranty by BioMarin or its Affiliates under this Agreement, and (ii) the research, development, manufacture, use or sale of any Licensed Product by BioMarin, its Affiliates or sublicensees hereunder,
regardless of the form in which any such claim is made, including: (x) any actual or alleged injury, damage, death or other consequence occurring to any person as a result, directly or indirectly, of the possession, use or consumption of any
Licensed Product manufactured, used or sold by BioMarin, its Affiliates or sublicensees hereunder, whether claimed by reason of breach of warranty, negligence, product defect or otherwise and (y) any use of the Licensed Technology, except to
the extent caused by WCH’s breach of this Agreement, or WCH’s negligence or willful misconduct. 
 (b) WCH agrees to Indemnify and
defend BioMarin, its agents, Affiliates, directors, officers and employees (the “BioMarin Indemnitee(s)”), at WCH’s sole expense, from and against any and all Losses, arising out or in connection with the material breach of any
representation or warranty by WCH or its Affiliates under this Agreement regardless of the form in which any such claim is made, including, any actual or alleged injury, damage, death or other consequence occurring to any person as a result,
directly or indirectly, of the breach. 
 (c) To be eligible to be so Indemnified as described in Section 9.4(a) or
Section 9.4(b), each of the WCH Indemnitees or BioMarin Indemnitees, as the case may be (the “Indemnitee(s)”), seeking to be Indemnified shall provide the Party required to 

 
Indemnify the Indemnitee(s) (the “Indemnifying Party”) with prompt notice of any claim (with a description of the claim and the nature and
amount of any such Loss) giving rise to the indemnification obligation pursuant to Section 9.4(a) or Section 9.4(b), as the case may be, and the exclusive ability to defend such claim but for the differing interest exception
set forth below (with the reasonable cooperation of Indemnitee(s)); provided, however, that the failure to provide notice shall not relieve the Indemnifying Party of its obligations except to the extent any failure by the Indemnitee(s) to
deliver prompt notice shall have been prejudicial to the Indemnifying Party’s ability to defend such action. Each Indemnitee(s) shall have the right to retain its own counsel in such action at its own expense or, if representation by the
counsel of the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnitee(s) and the Indemnifying Party, at the Indemnifying Party’s expense (provided that, the Indemnifying Party shall only
be responsible for any such expenses that are reasonable). Neither the Indemnitee(s) nor the Indemnifying Party shall settle or consent to the entry of any judgment with respect to any claim for Losses for which indemnification is sought, without
the prior written consent of the other Party (not to be unreasonably withheld or delayed); provided, however, that the Indemnifying Party shall have the right to settle or compromise any claim for Losses without such prior written consent if
the settlement or compromise provides for an unconditional release of the Indemnitee(s). The Indemnifying Party’s obligation to Indemnify the other Party’s Indemnitee(s) pursuant to this Section 9.4 shall not apply to the extent of
any Losses (a) that arise from the gross negligence or intentional misconduct of the other Party’s Indemnitee(s); or (b) that arise from the breach of this Agreement or any representation, warranty or covenant hereunder by the other
Party’s Indemnitee(s). 
 (d) Limitation of Liability. NEITHER PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL,
EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE, INCURRED BY THE OTHER PARTY IN CONNECTION WITH THIS AGREEMENT REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 

9.5 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are and shall otherwise be
deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code licenses of rights of “intellectual property” as defined in Section 101(35A) of the United States Bankruptcy Code. The Parties shall retain and may
fully exercise all of their respective rights and elections under the United States Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to, any such
intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.

 9.6 Publicity. Neither Party shall have the right to originate any publicity, news release or other public announcement, written or oral, relating
to this Agreement or the transactions contemplated hereunder, without the prior written approval of the other Party except as otherwise required by law. 
 9.7 Non-Use of Names. No license or right is granted hereunder to a Party to, and a Party shall not, use any name, trademark or logo, or the physical likeness or name of any employee of the other Party in any advertising, promotional
or sales literature, without the prior written consent of the other Party. 
 9.8 Assignment. Neither this Agreement nor any of the rights or
obligations hereunder may be assigned by either Party without the prior written consent of the other Party, except to a person or entity who acquires all or substantially all of the business of the assigning Party by merger, sale of assets or
otherwise. In the case of such an acquisition, the Party being acquired shall provide the other Party written notice within sixty (60) days of such acquisition. Any purported assignment in contravention of this Section 9.8 shall be
void. 
 9.9 Governing Law. This Agreement and its effect are subject to and shall be construed and enforced in accordance with the law of the State
of California, without regard to conflict of laws principles thereof. As between the Parties, any dispute, controversy or claim relating to this Agreement shall be submitted exclusively to a court of competent jurisdiction in San Francisco,
California. Each Party hereby submits to the jurisdiction of the courts located in San Francisco, California, both state and federal. 
 9.10 Waiver.
The waiver by either Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of
either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. 
 9.11 Notices. Any notice or other communication in connection with this Agreement must be in writing and shall be effective when delivered to the addressee at the address listed below or such other address as
the addressee shall have specified in a notice actually received by the addressor. 

 If to WCH: 
 Women and Children’s Hospital 
 72 King William Road 
 North Adelaide 
 South Australia, Australia 
 ATTN: Shaun Berg, Intellectual Property Management 
 If to BioMarin: 
 BioMarin Pharmaceutical Inc. 
 105 Digital Drive 
 Novato, California 94949 
 ATTN: General Counsel 
 9.12 No
Agency. Nothing herein shall be deemed to constitute either Party as the agent or representative of the other Party or both Parties as joint venturers or partners for any purpose. Neither Party shall be responsible for the acts or omissions of
the other Party, and neither Party will have authority to speak for, represent or obligate the other Party in any way without prior written authority from the other Party. 
 9.13 Entire Agreement. This Agreement contains the full understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating thereto, including
the License Agreement. No waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing and signed by the Parties by their respective officers thereunto duly authorized. 
 9.14 Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable or invalid, the validity and
enforceability of the remaining provisions shall not be affected, and the rights and obligations of the Parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be invalid or unenforceable.

 9.15 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their permitted successors and
assigns. Nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 
 9.16 Construction. The Parties agree that each Party has reviewed this Agreement and that any rule of construction to the effect that ambiguities are to be
resolved against the drafting Party shall not apply to the interpretation of this Agreement. As used herein, the term “including” shall mean “including, without limitation.” 
 9.17 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement. 
 9.18 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 (Signature Page Follows) 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as a sealed instrument in their names by
their properly and duly authorized officers or representatives as of the date first above written. 
  

					
	CHILDREN YOUTH AND WOMEN’S HEALTH SERVICE	 	
			
	By:	 	 /s/ RIMA STAUGAS
	 	
	Print Name:	 	RIMA STAUGAS	 	
	Title:	 	CHIEF EXECUTIVE	 	
		
	BIOMARIN PHARMACEUTICAL INC.	 	
			
	By:	 	 /s/ G. ERIC DAVIS
	 	
	Print Name:	 	G. ERIC DAVIS	 	
	Title:	 	VP, GENERAL COUNSEL	 	

 Exhibit A 
 WCH Licensed Technology 
  

			
	 Title
 Appln/Patent No.
	 	 Filing
 Issue
 Expiration

	 Precursor N-Acetylgalactosamine-4-Sulfatase,
 Methods Of Treatment Using Said Enzyme And
 Method For Producing And Purifying Said Enzyme
 Minmin Qin, Gary N. Zecherle, Dan J. Wendt, Wai-
 Pan Chan, Lin
Chen, Paul A. Fitzpatrick,
 Christopher M. Starr, Stuart Sweidler
 BioMarin Pharmaceutical Inc.
	 	
		
	 6,866,844
 10/290,908
 United States
	 	 11/07/02
 03/15/05
 11/07/22

		
	 11/135,264
 United States
	 	 05/23/05
 Pending
 11/07/22

		
	 Publication No. AR 042019
 P0301041118
 Argentina
 Based on U.S. Application no. 10/290,908
	 	 11/07/03
 Pending
 11/07/13

		
	 092131341
 Taiwan
 Based on U.S. Application no. 10/290,908
	 	 11/07/03
 Pending
 11/07/13

		
	 2003290642
 PCT/US2003/035510
 Australia
	 	 11/07/03
 Pending
 11/07/23

		
	 PI 0316039-4
 PCT/US2003/035510
 Brazil
	 	 11/07/03
 Pending
 11/07/23

		
	 PCT/US2003/035510
 Canada
	 	 11/07/03
 Pending
 11/07/23

		
	 200380105922.9
 PCT/US2003/035510
 China
	 	 11/07/03
 Pending
 11/07/23

		
	 03783223.5
 PCT/US2003/035510
 Europe
	 	 11/07/03
 Pending
 11/07/23

		
	 168435
 PCT/US2003/035510
 Israel
	 	 11/07/03
 Pending
 11/07/23

		
	 2098/DELNP/2005
 PCT/US2003/035510
 India
	 	 11/07/03
 Pending
 11/07/23

			
	Title
Appln/Patent No.	 	 Filing
Issue
Expiration

	 2004-551853
 PCT/US2003/035510
 Japan
	 	 11/07/03
 Pending
 11/07/23

		
	 PA/a/2005/004880
 PCT/US2003/035510
 Mexico
	 	 11/07/03
 Pending
 11/07/23

		
	 Enzymes Useful For Treating and methods for
 Treating MPS-VI and Cell Lines for Producing
 Such Enzymes Recombinantly
 Christopher M. Starr
 BioMarin Pharmaceutical Inc.
	 	
		
	 2,443,555
 Canada
	 	 04/25/01
 Pending
 05/01/20

		
	 2001255771
 Australia
	 	 04/25/01
 Pending
 04/25/13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]